Vertex Pharmaceuticals Inc
VRTX462.130USD
+5.260+1.15%
Handelsschluss 08/01, 16:00（ET）Kurse um 15 Minuten verzögert
118.75BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Unternehmensinformationen
BörsenkürzelVRTX
Name des UnternehmensVertex Pharmaceuticals Inc
IPO-datumJul 24, 1991
Gegründet am1989
CEODr. Reshma Kewalramani
Anzahl der mitarbeiter6100
WertpapierartOrdinary Share
GeschäftsjahresendeJul 24
Addresse50 Northern Avenue
StadtBOSTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02210
Telefon16173416393
Websitehttps://www.vrtx.com/
BörsenkürzelVRTX
IPO-datumJul 24, 1991
Gegründet am1989
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.65B
59.91%
Europe
826.60M
29.95%
Other
280.10M
10.15%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Aktionärsstatistik
Aktualisiert: Thu, May 15
Aktualisiert: Thu, May 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Aktionäre
Aktionäre
Anteil
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
59.72%
Investment Advisor/Hedge Fund
28.09%
Research Firm
2.55%
Pension Fund
2.35%
Bank and Trust
2.04%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.29%
Insurance Company
0.16%
Individual Investor
0.14%
Other
2.22%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
2926
251.46M
97.92%
+1.75M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
28.53M
11.11%
+207.61K
+0.73%
Mar 31, 2025
The Vanguard Group, Inc.
23.38M
9.1%
+232.41K
+1.00%
Mar 31, 2025
Capital Research Global Investors
14.54M
5.66%
+4.11M
+39.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.00M
5.45%
-330.35K
-2.31%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.59%
-190.75K
-1.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
2.97%
-1.49M
-16.32%
Mar 31, 2025
Jennison Associates LLC
5.06M
1.97%
+744.68K
+17.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.76M
2.24%
+113.52K
+2.01%
Mar 31, 2025
Wellington Management Company, LLP
5.45M
2.12%
-461.34K
-7.80%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
5.31M
2.07%
-20.76K
-0.39%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 47 minutes ago
Aktualisiert: 47 minutes ago
Name
Anteil
VanEck Biotech ETF
10.59%
Tema Neuroscience and Mental Health ETF
10.48%
ProShares Ultra Nasdaq Biotechnology
7.77%
Invesco Nasdaq Biotechnology ETF
7.77%
iShares Biotechnology ETF
6.83%
Invesco Biotechnology & Genome ETF
4.86%
Natixis Loomis Sayles Focused Growth ETF
4.46%
Franklin Genomic Advancements ETF
4.34%
Global X Genomics & Biotechnology ETF
3.55%
Tema Heart & Health ETF
3.25%
Mehr Anzeigen
VanEck Biotech ETF
Anteil10.59%
Tema Neuroscience and Mental Health ETF
Anteil10.48%
ProShares Ultra Nasdaq Biotechnology
Anteil7.77%
Invesco Nasdaq Biotechnology ETF
Anteil7.77%
iShares Biotechnology ETF
Anteil6.83%
Invesco Biotechnology & Genome ETF
Anteil4.86%
Natixis Loomis Sayles Focused Growth ETF
Anteil4.46%
Franklin Genomic Advancements ETF
Anteil4.34%
Global X Genomics & Biotechnology ETF
Anteil3.55%
Tema Heart & Health ETF
Anteil3.25%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
